Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ROCKET PHARMACEUTICALS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
0
0
0
0
0
0
0
Research and development
5.99
14.9
53.3
57.9
105
125
166
186
171
142
General and administrative
1.58
4.86
17.9
18.2
28.9
41.8
58.8
73.3
102
86.5
Operating expenses
7.57
19.8
71.2
76.2
134
167
224
260
273
232
Operating income
-7.57
-19.8
-71.2
-76.2
-134
-167
-224
-260
-273
-232
Interest expense
0
0
6.04
5.96
6.97
2.98
1.86
1.88
1.89
1.89
Interest income
0.44
0.82
Other non-operating income
-5.4
-1.82
2.48
Pre-tax income
-259
-223
Income tax
0
0
0
Net income
-7.57
-19.6
-74.5
-77.3
-140
-169
-222
-246
-259
-223
EBITDA
-7.51
-19.6
-70.8
-75.7
-133
-164
-220
-255
-266
-223
EPS, basic
-1.11
-2.88
-1.89
-1.58
-2.52
-2.67
-3.26
-2.92
-2.73
-2.01
EPS, diluted
-1.11
-2.88
-1.89
-1.58
-2.52
-2.67
-3.26
-2.92
-2.73
-2.01
Shares, basic (weighted)
6.83
6.8
39.4
49
55.4
63.2
68.1
84
94.8
111
Shares, diluted (weighted)
6.83
6.8
39.4
49
55.4
63.2
68.1
84
94.8
111
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
29.8
18.1
111
185
297
233
141
55.9
164
77.6
Short-term investments
96.7
0
94.4
119
186
156
216
317
209
111
Other current assets
1.88
0.81
3.36
3.64
4.63
3.32
7.67
5.05
5.85
3.81
Total current assets
128
19
209
308
487
392
364
378
378
193
Property, plant and equipment
1.13
0.99
2.03
29.5
19.2
22.3
29
39.2
36.8
28.2
Lease right-of-use assets
0
2.05
0.91
1.57
1.97
3.9
4.17
3.21
Goodwill
0
30.8
30.8
30.8
30.8
39.2
39.2
39.2
39.2
Intangible assets
0
25.7
25.2
25.2
25.2
Long-term investments
0
7.4
0
0
43.3
34.3
0
Other non-current assets
0.17
0.17
Total assets
130
20.1
251
372
591
497
552
566
528
330
Accounts payable
1.59
0
15.4
17.4
25.5
19.6
36.7
45.8
37.8
27.3
Accrued liabilities
4.25
2.37
2.59
4.88
4.53
10
9.93
11.9
12.3
Total current liabilities
7.04
4.52
15.4
18.3
32.6
22.2
39.2
48.5
40.7
30.2
Lease liabilities
0
1.44
0.5
0.91
1.09
2.97
3.26
2.6
Other non-current liabilities
0.48
0.4
0.46
0.02
0.14
0.08
2.6
2.94
1.14
1.06
Total liabilities
56.5
4.63
57.3
64.8
87.3
42.3
62.1
73.8
64.5
53.2
Paid-in capital
312
5.34
300
490
826
946
1,203
1,451
1,680
1,717
Retained earnings
-239
-31.4
-106
-183
-323
-492
-714
-959
-1,218
-1,441
Treasury stock
0
-0.67
-0.05
0
0
-0.05
0
Other comprehensive income
-0.05
0
-0.13
0.02
-0.04
-0.16
-0.36
0.32
0.07
-0.03
Shareholders' equity
8.37
15.5
194
307
504
455
490
493
463
277
Total equity
8.37
15.5
194
307
504
455
490
493
463
277
Total liabilities and equity
130
20.1
251
372
591
497
552
566
528
330
Shares outstanding
6.75
6.8
45.1
54.8
61
64.5
79.1
90.3
106
108
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-7.57
-19.6
-74.5
-77.3
-140
-169
-222
-246
-259
-223
Depreciation and amortization
0.07
0.2
0.33
0.43
1.15
3.2
3.9
4.9
7.2
8.9
Stock-based compensation
0.27
1.32
13.6
13.4
18.6
29.2
31
39.4
43.9
37.1
Change in payables
-0.04
-1.14
5.89
-2.72
11
-4.83
9.67
10.1
6.07
-10.4
Cash from operations
-5.5
-16
-53.8
-64.7
-74.6
-121
-178
-195
-210
-190
Capital expenditures
-0.34
-0.76
-1.45
-23.3
-20.6
-7.62
-8.36
-16.4
-5.86
-0.44
Purchases of investments
0
0
-141
-184
-209
-246
-376
-391
-246
-277
Cash from investing
-0.34
-0.76
-5.27
-39
-96.6
18.9
-69.3
-98.1
132
104
Stock issued
0
0
154
0.03
0
0
46.6
2.23
3.21
0
Share buybacks
0
0
0
0
-0.07
0
Cash from financing
0.02
25.4
154
178
283
37.7
155
208
186
0.15
Net change in cash
-50.2
48.9
94.4
74.1
112
-64.6
-92.2
-84.6
108
-86.1
Free cash flow
-5.84
-16.7
-55.2
-87.9
-95.2
-129
-187
-211
-216
-190
Interest paid
0
0
4.49
2.99
2.96
0.15
0
0
Income taxes paid
0
0
0
0.03
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.60 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-4.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-4.1%
Net income / average total assets.
Return on invested capital (ROIC)
-104.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-40.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-17.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-11.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-37.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-15.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-11.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
17.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
17.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
14.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.24x
Current assets / current liabilities.
Quick ratio
9.06x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
9.06x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
FCF per share
-$1.49
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.49
Cash from operations / diluted weighted shares.
Book value per share
$3.37
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.77x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.94x
Market cap / tangible book value, when positive.
FCF yield
-59.8%
Free cash flow / market cap.
Earnings yield
-6.1%
Net income / market cap (the inverse of P/E).
What was ROCKET PHARMACEUTICALS, INC.'s revenue in fiscal 2025?
ROCKET PHARMACEUTICALS, INC. reported revenue of $0.0 for fiscal 2025.
Was ROCKET PHARMACEUTICALS, INC. profitable in fiscal 2025?
No. It reported a net loss of $223.1M.
How much free cash flow did ROCKET PHARMACEUTICALS, INC. generate in fiscal 2025?
Cash from operations of $190.0M minus capital expenditures of $440.0K left free cash flow of -$190.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.